RxDoctor Payments Data

Marizol Fontanez, PA

Medical · Orlando, FLNPI 1801896808

Payments from drug & device makers

$1,393in general payments, 2019–2025

Across 33 payments — averaging $42.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$535
  • AstraZeneca$215
  • Bayer$162
  • Amgen$147
  • Ardelyx, Inc.$112
  • Akebia Therapeutics Inc$93
  • plus $130 from 5 others

What the payments were for

  • Food & beverage$1,393100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,393 in reported general payments places this provider in the 60th percentile of 2,031 medical providers in Florida.

See all medical providers in Florida

Medicare billing

Part B allowed, 2024
$16,033
Medicare patients
33
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XphozahTenapanor Hcl36$148,224
VelphoroSucroferric Oxyhydroxide23$56,976
Sevelamer Carbonate181$31,772
AuryxiaFerric Citrate13$22,354
ClinisolParenteral Amino Acid 15% No.549$11,679
ClinolipidFat Emulsion/Olive/Soy/Phospho47$11,468
LokelmaSodium Zirconium Cyclosilicate22$11,420
ProsolParenteral Amino Acid 20% No.138$9,458
Calcium Acetate42$2,337
Midodrine Hcl17$1,581
Nifedipine ErNifedipine52$1,053
Hydralazine Hcl42$533
Amlodipine Besylate45$406
Losartan Potassium49$378
Torsemide16$212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$535$56,97623 claims
Akebia Therapeutics IncAuryxia$93$22,35413 claims
AstraZenecaLokelma$215$11,42022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,031 medical providers in Florida.

Other medical in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →